ライフサイエンスコーパス: serogroup

1 pneumococcal disease changes by serotype and serogroup.

2 anifestation and less on meningococcal CC or serogroup.

3 ent of septic shock was not related to CC or serogroup.

4 001) and not affected by comorbidity, CC, or serogroup.

5 ), a naturally attenuated member of the TBEV serogroup.

6 revalence of 2.6-69.3% of positive swabs per serogroup.

7 d simultaneous detection of three Salmonella serogroups.

8 caused by Vibrio cholerae of the O1 or O139 serogroups.

9 rried by adulterant or nonadulterant E. coli serogroups.

10 ogroup (67%) and included a diverse array of serogroups.

11 ing units/ml) for both toxigenic V. cholerae serogroups.

12 in survivors was comparable between the two serogroups.

13 train genotypes among vaccine and nonvaccine serogroups.

14 more resistant to human LL-37 than other GAS serogroups.

15 de some protection against all meningococcal serogroups.

16 trains 6077, 6206 (serogroup O11), and PA14 (serogroup 010) were less sensitive to NET capture.

17 SBT) analysis of all incoming L. pneumophila serogroup 1 (Lp1) isolates to identify potential links b

18 nd 2013 L. pneumophila patient isolates were serogroup 1 and closely related to all 2013 hospital wat

19 Because Legionella pneumophila serogroup 1 is responsible for >85% of infections, the m

20 the genus Legionella; Legionella pneumophila serogroup 1 is the causative agent of most cases in Euro

21 L. pneumophila serogroup 1 isolates (n = 106) from the standard "typing

22 Legionella pneumophila serogroup 1 isolates were cultured from patient sputum (

23 monly used laboratory strains: L pneumophila serogroup 1 Philadelphia (Phil-1)-derived strains JR32 a

24 alyses of 43 strains, including all known Lp serogroups 1-17 and 17 emergent LD-causing Legionella sp

25 L. pneumonphila (LP) serogroup-1 (Lp1) is the major cause of Legionnaires' Di

26 In 2015, serogroup 15 outnumbered 19A, to become the leading sero

27 in mothers, and the most prevalent NVTs were serogroup 16 and nontypeables, respectively.

28 sh Streptococcus pneumoniae serotypes within serogroup 18 from culturable/nonculturable pneumococcal

29 s fell into a single lineage associated with serogroup 23, which had an origin in 1908 as dated by co

30 B2.1 phylogenetic subgroup (56%) and O1 serogroup (27.7%) were the most frequently identified.

31 es (91%) were contaminated by L. pneumophila serogroups 3 and 10.

32 of E. coli was 30% (n = 48) distributed in 8 serogroups (40/48, 83.3%), while 8 isolates (8/48, 16.6%

33 ed a diverse data set of approximately 1,000 serogroup 6 genomes, assessed the prevalence and distrib

34 Genetic studies of serogroup 6 isolates ofStreptococcus pneumoniaeidentifie

35 Within the serotypes, serogroup 6 pneumococci are a frequent cause of serious

36 ype 6E, analyzed the genetic diversity among serogroup 6 pneumococci, and investigated whether pneumo

37 The number of N. meningitidis serogroup A (NmA) among confirmed bacterial meningitis c

38 of meningitis due to Neisseria meningitidis serogroup A (NmA) has substantially decreased.

39 ccal serogroup C vaccine in 2, meningococcal serogroup A and Haemophilus influenzae type b vaccine ea

40 32 serogroup A carriers were identified in 4278 age-stratif

41 A novel meningococcal serogroup A conjugate vaccine (MACV [MenAfriVac]) was de

42 After successful meningococcal serogroup A conjugate vaccine (MACV) campaigns since 201

43 belt of sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has been progressiv

44 With the rollout of a novel meningococcal serogroup A conjugate vaccine (MACV) in the belt, the Wo

45 In 2010-2017, meningococcal serogroup A conjugate vaccine (MACV) was introduced in 2

46 Meningococcal serogroup A conjugate vaccine (MACV) was introduced in C

47 tis epidemiology and impact of meningococcal serogroup A conjugate vaccine (MACV).

48 ted vaccination campaigns with meningococcal serogroup A conjugate vaccine (MACV).

49 is belt countries introduced a meningococcal serogroup A conjugate vaccine (MACV).

50 following the introduction of meningococcal serogroup A conjugate vaccine in 2010.

51 rogressive introduction of the meningococcal serogroup A conjugate vaccine within Africa's meningitis

52 introduction and rollout of a meningococcal serogroup A conjugate vaccine, MenAfriVac, in the Africa

53 to receive either Vi-TCV or a meningococcal serogroup A conjugate vaccine.

54 e capsular polysaccharide (CPS), which in Nm serogroup A consists of N-acetyl-mannosamine-1-phosphate

55 To combat Neisseria meningitidis serogroup A epidemics in the meningitis belt of sub-Saha

56 meningitis belt where Neisseria meningitidis serogroup A historically caused large-scale epidemics.

57 eningitis belt, where Neisseria meningitidis serogroup A historically caused large-scale epidemics.

58 In Burkina Faso, serogroup A meningococcal (NmA) conjugate vaccine (PsA-T

59 s were conducted after introduction of a new serogroup A meningococcal conjugate vaccine (MenAfriVac)

60 MACV impact, characterized the burden of non-serogroup A meningococcal disease (including the emergen

61 n the African meningitis belt has eliminated serogroup A meningococcal infections for >300 million Af

62 cal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic.

63 Despite enhanced surveillance, no case of serogroup A meningococcal meningitis was reported in the

64 A serogroup A meningococcal polysaccharide-tetanus toxoid

65 months before vaccination, whereas only one serogroup A meningococcus was isolated in 5001 people li

66 devastating outbreaks, largely attributed to serogroup A Neisseria meningitidis (MenA).

67 although high coverage with MACV has reduced serogroup A outbreaks, large meningococcal meningitis ou

68 MenAfriVac vaccination against meningococcal serogroup A to prevent meningitis outbreaks in the north

69 tion campaign against Neisseria meningitidis serogroup A was carried out in 2010-2011.

70 rogroups were confirmed in 3917 (75%) cases: serogroup A was present in 4.7% of cases, B in 23.3%, C

71 accinated with meningococcal serogroup B and serogroup A, C, W, Y vaccines.

72 s one such lineage of meningococci, known as serogroup A, clonal complex 5 (A:cc5), has caused three

73 gainst infection with Neisseria meningitidis serogroup A, we use an assumed SBA titre of 128 as a thr

74 ular polymerases from Neisseria meningitidis serogroups A (CsaB) and X (CsxA) were characterized.

75 Neisseria meningitidis serogroups A and X are among the leading causes of bacte

76 polyhexosamine phosphates in N. meningitidis serogroups A and X.

77 e is mainly caused by Neisseria meningitidis serogroups A, B, C, X, W, and Y.

78 Meningococcal conjugate vaccines against serogroups A, C, W, and Y (MenACWY) are recommended for

79 ived from hydrolysis of mixtures of the four serogroups A, C, W, and Y reference polysaccharides.

80 vaccines are available against meningococcal serogroups A, C, W, and Y.

81 All serogroups, A-I, were detected by PCR in 687/1150 D. nod

82 ered within, flocks, with 50 combinations of serogroups across flocks.

83 nd disease outcome of IMD-W cases with other serogroups, adjusting for host characteristics.

84 nity-based outbreaks differed in predominant serogroup, age distribution of cases, and clinical syndr

85 eactivity with viruses belonging to the same serogroup and by long-lasting antibodies from prior infe

86 s closely related to CCHFV, sharing the same serogroup and many structural, biochemical, and cellular

87 servations highlight the difficulties in the serogrouping and capsular genogrouping of meningococcal

88 ant against threats from other meningococcal serogroups and other pathogens.

89 animal pathogens classified within multiple serogroups and species.

90 "top 7" Shiga toxin-producing E. coli (STEC) serogroups and were declared by the USDA as adulterants

91 of age, comorbidity, clinical manifestation, serogroup, and CC on disease course and outcome was asse

92 In Sweden, serogroup Y is now the dominating serogroup, and in 2012, the serogroup Y disease incidenc

93 thesis (cps) locus, classify N. meningitidis serogroups, and identify mechanisms for nongroupability

94 strains belonging to the hypervirulent M1T1 serogroup are more resistant to human LL-37 than other G

95 The capsule polymerases (CPs) of these serogroups are members of the Stealth protein family com

96 f the randomly selected STEC belonged to key serogroups associated with human disease and none encode

97 quadrivalent glycoconjugate (MenACWY-CRM) or serogroup B (4CMenB) vaccination on meningococcal carria

98 ecember 2013, a multicomponent meningococcal serogroup B (4CMenB) vaccine was used before licensure o

99 present with severe disease than those with serogroup B (aRRR 2.7, 95% CI 1.1-6.3); HIV coinfection

100 Neisseria meningitidis serogroup B (MnB) is a leading cause of bacterial mening

101 nsed vaccines against Neisseria meningitidis serogroup B (NmB) will depend partly on disease burden e

102 Serogroup B accounted for 8 (47.1%) of the organization-

103 er milliliter (90 596 and 114 683 CFU/mL for serogroup B and C strains, respectively; P < .0001 compa

104 healthy adults vaccinated with meningococcal serogroup B and serogroup A, C, W, Y vaccines.

105 ed any meningococcal bacteria and 4% carried serogroup B by rt-PCR.

106 dly reduce meningococcal carriage or prevent serogroup B carriage acquisition.

107 Total meningococcal and genotypically serogroup B carriage prevalence among sampled students w

108 nB-4C was associated with decreased total or serogroup B carriage prevalence.

109 Ten students acquired serogroup B carriage: 3 after 1 MenB-FHbp dose, 4 after

110 d in the USA for prevention of meningococcal serogroup B disease in 10-25-year-olds.

111 vasive meningococcal disease cases caused by serogroup B has increased.

112 s regarding which vaccine to use in managing serogroup B IMD outbreaks require information about the

113 Immunization registry data and serogroup B invasive meningococcal disease (B-IMD) cases

114 Serogroup B is the primary cause of organization-based o

115 MenB-FHbp (factor H binding protein), a serogroup B meningococcal (MenB) vaccine, was used to co

116 Limited data exist on the impact of the serogroup B meningococcal (MenB) vaccines MenB-FHbp and

117 ave been used for the prevention of invasive serogroup B meningococcal disease (IMD) since their lice

118 Serogroup B meningococcal disease caused 7 US university

119 ination campaign in response to a university serogroup B meningococcal disease outbreak in 2015.

120 uced 4CMenB-a multicomponent vaccine against serogroup B meningococcal disease-into the national infa

121 in-based vaccine licensed to protect against serogroup B meningococcal disease.

122 Invasive serogroup B meningococcal isolates from cases in England

123 revention of sepsis and meningitis caused by serogroup B meningococci.

124 nt of two recently licensed vaccines against serogroup B meningococcus (MenB).

125 Serogroup B Neisseria meningitidis (MenB) is a major cau

126 Among 25 serogroup B Neisseria meningitidis clinical isolates, we

127 hogens isolated, 102 (76.1%) were Salmonella serogroup B or D.

128 uebec, starting in 2003, and was caused by a serogroup B sequence type 269 clone.

129 512) strains, thereby providing at least 82% serogroup B strain coverage.

130 Bexsero and Trumenba, against meningococcal serogroup B strains have been licensed; both vaccines co

131 eningococcal disease caused by meningococcal serogroup B strains.

132 mplement (hSBA) by use of four meningococcal serogroup B test strains expressing vaccine-heterologous

133 participants for three of four meningococcal serogroup B test strains representative of disease-causi

134 participants for three of four meningococcal serogroup B test strains representative of disease-causi

135 The multicomponent meningococcal serogroup B vaccine (4CMenB) is an outer membrane vesicl

136 immunized rhesus macaques with a 4-component serogroup B vaccine (4CMenB).

137 nsider the implementation of a meningococcal serogroup B vaccine for young children and/or serogroup

138 MenB-4C is a recently licensed meningococcal serogroup B vaccine.

139 ble herd immunity effects with meningococcal serogroup B vaccines and the need for a booster dose to

140 In contrast, 2 licensed meningococcal serogroup B vaccines, including one containing detergent

141 the majority of university outbreaks due to serogroup B, and serogroup C is the primary cause of com

142 ity of IMD-W with IMD caused by meningococci serogroup B, Y, or C, adjusting for age, gender, and com

143 d genomes identified a diverse collection of serogroups (B, C1, C2 to C3, D1, E1, G, I, K, N, O, and

144 r against an isolate obtained from a rodent (serogroup Ballum).

145 , the majority of studies have examined this serogroup, but there are 3 commonly used laboratory stra

146 am-negative Neisseria meningitidis, capsular serogroup C (MenC) or Gram-positive group B Streptococcu

147 Neisseria meningitidis serogroup C (NmC) was responsible for 59% (10/17) of ser

148 tive specimens, 14 (88%) were N meningitidis serogroup C (NmC), 1 was NmW, and 1 was nongroupable.

149 71.5%) that were positive for N meningitidis serogroup C (NmC).

150 Serogroup C accounted for 10 (52.6%) of the community-ba

151 Serogroup C accounted for 11 outbreaks and W for 6.

152 N. meningitis serogroup C belonging to the hypervirulent clonal comple

153 increase in the incidence of serogroup W and serogroup C between both countries.

154 of isolates from clonal complexes with high serogroup C capsule expression rate during carriage (seq

155 of cssA/B/C and a part of csc, encoding the serogroup C capsule polymerase.

156 5 all provinces introduced the meningococcal serogroup C conjugate vaccine (MCCV) into their routine

157 lance data for meningococcal serogroup W and serogroup C disease in the Netherlands and England for t

158 meningococcal serogroup W with meningococcal serogroup C emergence, the rapid expansion of the MenW:c

159 MCCV dramatically reduced the incidence of serogroup C IMD in Canada through both direct and indire

160 university outbreaks due to serogroup B, and serogroup C is the primary cause of community-based outb

161 elong to a highly virulent and predominantly serogroup C lineage, including strains that are able to

162 Several clusters of serogroup C meningococcal disease among men who have sex

163 After the re-emergence of serogroup C meningococcal meningitis (MM) in Nigeria and

164 erogroup B vaccine for young children and/or serogroup C or ACWY conjugate vaccine for adolescents.

165 rent serogroup W outbreak and the historical serogroup C outbreak, the increase in incidence started

166 Netherlands and England, and the historical serogroup C outbreaks in both countries.

167 isolates from cluster-associated cases were serogroup C sequence type 11.

168 ococcal vaccine in 9 patients, meningococcal serogroup C vaccine in 2, meningococcal serogroup A and

169 admissions decreased after the meningococcal serogroup C vaccine was introduced in 1999 and was 12.40

170 ing the emergence of a new epidemic clone of serogroup C), and documented the impact of pneumococcal

171 However, serogroup C, W, and X meningococci continue to circulate

172 ns of hypervirulent meningococcal strains of serogroup C:cc11 by phylogenomic time trees.

173 Non-A serogroups C/W/X are now the most prevalent.

174 he clinical presentation of infection due to serogroups C/W/X includes nonmeningeal IMD, and there is

175 disease (IMD) isolates, which can be readily serogrouped, carriage isolates often lack capsule expres

176 NmC is the predominant serogroup causing N. meningitidis meningitis.

177 rimean-Congo hemorrhagic fever virus (CCHFV) serogroup comprises sole members CCHFV and Hazara virus

178 uence-specific PCRs to identify 74 serotypes/serogroups covering all current vaccine types as well as

179 Although related, these V. cholerae serogroups differ in several fundamental ways, in terms

180 There was a significant change (P < .05) in serogroup distribution among all age groups between the

181 Core surveillance (ABCs) were characterized; serogroup distribution and molecular features of these i

182 Niger's dynamic Nm serogroup distribution highlights the need for strong su

183 e to horizontal gene transfer and changes in serogroup distribution.

184 nce of invasive meningococcal disease due to serogroup E in Queensland, Australia, in previously heal

185 lates was retained for all serogroups except serogroup E which has a synthetic requirement for UDP-Ga

186 cs have been eliminated here; however, non-A serogroup epidemics continue.

187 meningococcal isolates was retained for all serogroups except serogroup E which has a synthetic requ

188 the phenotypic methods correctly identified serogroups for 69 to 98% of IMD isolates.

189 hereas none of the participants in the other serogroups had such responses.

190 The commercial vaccine, containing nine serogroups, has low efficacy compared with bivalent vacc

191 Toxigenic Vibrio cholerae of the O139 serogroup have been responsible for several large choler

192 e-fatality ratio associated with these non-A serogroups; however, data on the nonmeningeal IMD burden

193 bodies were directed most frequently against serogroups Icterohaemorrhagiae (22.0%) and Autumnalis (1

194 Compared with other serogroups, IMD-W patients were diagnosed more often wit

195 onsible for the increased prevalence of this serogroup in Sweden.

196 against footrot and, with 50 combinations of serogroups in flocks, flock-specific vaccines are necess

197 ate detection and confirmation of major STEC serogroups in high-throughput settings.

198 ribution, and annual changes in serotype and serogroup, including changes in vaccine-type Spn meningi

199 s compared with controls and group B and all serogroup invasive meningococcal disease in cases compar

200 The secondary outcomes were all serogroup invasive meningococcal disease in fully vaccin

201 ]; OR, 0.18 [95% CI, 0.08-0.44]) and for all serogroup invasive meningococcal disease, 11 of 98 cases

202 For all serogroup invasive meningococcal disease, 6 of 85 cases

203 This serogroup is presently classified into 19 serotypes worl

204 The serogroup is typically determined by slide agglutination

205 Vibrio cholerae belonging to the O1 and O139 serogroups is commonly associated with epidemic diarrhea

206 ethods were evaluated for their abilities to serogroup isolates and were compared with two genotyping

207 Because the N. meningitidis serogroup L capsule polymer consists of a trimeric repea

208 esis of the complex trimeric N. meningitidis serogroup L capsule polymer repeating unit.

209 hysiologically less relevant N. meningitidis serogroup L, is one of the smallest known Stealth protei

210 ingococcal meningitis outbreaks due to other serogroups may continue to occur; effective multivalent

211 Outbreaks due to non-A serogroup meningococci continue to be a significant burd

212 Our WGS-based serogrouping method provides comprehensive characterizat

213 p C (NmC) was responsible for 59% (10/17) of serogrouped N. meningitidis meningitis.

214 the classical and El Tor biotype strains of serogroup O1 that is most frequently associated with epi

215 holerae O139 isolates are closely related to serogroup O1, biotype El Tor V. cholerae, and comprise a

216 rrhoeal disease caused by certain strains of serogroup O1/O139 Vibrio cholerae.

217 V. cholerae serogroups O1 and O139 are responsible for cholera outbr

218 isolates of the seventh pandemic V. cholerae serogroups O1 and O139 biotype El Tor(2-4).

219 h the detection of toxigenic Vibrio cholerae serogroups O1 and O139, which are associated with choler

220 cytotoxic P. aeruginosa strains 6077, 6206 (serogroup O11), and PA14 (serogroup 010) were less sensi

221 higa toxin-producing Escherichia coli (STEC) serogroup O121 and O26 infections linked to contaminated

222 Escherichia coli serogroups O157, O26, O45, O103, O111, O121, and O145, w

223 ile the invasive P. aeruginosa strains PAO1 (serogroup O5) and 6294 (serogroup O6) were trapped by NE

224 in intestinal colonization of cattle by EHEC serogroup O5, O111, and O26 strains.

225 ginosa strains PAO1 (serogroup O5) and 6294 (serogroup O6) were trapped by NETs, the cytotoxic P. aer

226 Serotyping and serogrouping of Salmonella isolates was performed using

227 vestigate the prevalence and distribution of serogroups of D. nodosus in England to elucidate whether

228 ing the smpB gene was designed to detect all serogroups of H. influenzae.

229 Twenty adults were enrolled in each of 3 serogroups of individuals: those negative for both HSV1

230 Keystone virus, a California-serogroup orthobunyavirus, was first isolated in 1964 fr

231 In contrast, V. cholerae serogroups other than O1 and O139, also designated as V.

232 trains (P = .014) and severe disease with O7 serogroup (P = .034) and PapGII adhesin (OR, 2.3 [95% CI

233 Co-occurrence of between-serogroup pairs was more common when both serotypes had

234 There was a median of two serogroups per flock (range 0-6).

235 Since top 7 serogroup-positive cattle feces and ground beef can also

236 H and B were the most prevalent serogroups, present in > 60% of flocks separately but in

237 rane protein (rMOMP) vaccine to elicit cross-serogroup protection.

238 The differences between IMD-W and other serogroups remained after adjusting for age, gender, and

239 Vaccine-induced serogroup replacement was not observed, although a small

240 typically determined by slide agglutination serogrouping (SASG) and real-time PCR (RT-PCR).

241 irmed and N. meningitidis/H. influenzae were serogrouped/serotyped by real-time polymerase chain reac

242 be used to detect and associate the E. coli serogroup-specific gene with major virulence genes and d

243 ed space-time analyses to detect clusters of serogroup-specific IMD cases.

244 We identified 8 serogroup-specific, geo-temporal clusters of disease.

245 Death was associated with uncommon O serogroup strains (P = .014) and severe disease with O7

246 w insights into the biology of a V. cholerae serogroup that, from a genomic perspective, is poorly un

247 We were unable to serogroup the N. meningitidis cases by PCR.

248 Of these serogroups, the Crimean-Congo hemorrhagic fever virus (C

249 The predominant Nm serogroups varied over time (NmW in 2010-2011, NmC in 20

250 and H. influenzae belonged to meningococcus serogroup W (45.5%) and H. influenzae type b (54.5%), re

251 ease in invasive meningococcal disease (IMD) serogroup W (IMD-W) cases caused by sequence type-11 clo

252 has been found in the Neisseria meningitidis serogroup W (NmW) capsular polysaccharide (CPS) and is a

253 enced its first major Neisseria meningitidis serogroup W (NmW) outbreak.

254 annual relative increase in the incidence of serogroup W and serogroup C between both countries.

255 national surveillance data for meningococcal serogroup W and serogroup C disease in the Netherlands a

256 meningococcal and H. influenzae strains were serogroup W and serotype b, respectively.

257 ith an increased risk of IMD, especially for serogroup W and Y diseases.

258 other affected countries to prevent further serogroup W cases and deaths.

259 Cases due to meningococcal serogroup W cc11 (MenW:cc11) emerged in 2012-13 in the N

260 Since 2009, the incidence of meningococcal serogroup W disease has increased rapidly in the UK beca

261 Netherlands, the incidence of meningococcal serogroup W disease increased substantially in 2015-16 c

262 me multilocus sequence typing (1546 loci) on serogroup W disease isolates from both countries for sur

263 n increase in the incidence of meningococcal serogroup W disease.

264 For both the current serogroup W outbreak and the historical serogroup C outb

265 al and phylogenetic associations between the serogroup W outbreaks in the Netherlands and England, an

266 o a sublineage of the Neisseria meningitidis serogroup W ST-11 clonal complex (hereafter, the "origin

267 Patients with serogroup W were 3 times more likely to present with sev

268 the historical similarities of meningococcal serogroup W with meningococcal serogroup C emergence, th

269 In the serogroups W and Y, these are heteropolymers of the repe

270 This serogroup was initially feared to represent a new, emerg

271 The IRR for non-A serogroups was higher after completion of MenAfriVac cam

272 Serogroups were confirmed in 3917 (75%) cases: serogroup

273 ence genes carried by each of the top 7 STEC serogroups were detected by dPCR with appropriately dilu

274 Twenty-one serotypes/serogroups were detected by qPCR compared to 14 by CCBM.

275 only H and B present) and partially, if more serogroups were present in the flock.

276 Serogroups were randomly distributed between, but cluste

277 d SASG were in 91% to 100% agreement for all serogroups, while the results of WGS and RT-PCR showed 9

278 was defined as >=2 primary cases of the same serogroup within <3 months in an organization, or a >=2-

279 ntly, a bivalent vaccine targeting these two serogroups would protect 27% of flocks fully (if only H

280 Serogroup Y (MenY) strains are a major cause of meningoc

281 w the dominating serogroup, and in 2012, the serogroup Y disease incidence was 0.46/100,000 populatio

282 jective of this study was to investigate the serogroup Y emergence by whole-genome sequencing and com

283 delineating them, in order to understand the serogroup Y emergence.

284 sease (IMD) caused by Neisseria meningitidis serogroup Y has increased in Europe, especially in Scand

285 s strain was responsible for the increase of serogroup Y IMD in Sweden.

286 These data suggest that the serogroup Y IMD increase in Sweden was most probably due

287 to 2012 (n = 143), which had relatively low serogroup Y incidence, and two isolates obtained in 1999

288 In Sweden, serogroup Y is now the dominating serogroup, and in 2012

289 -genome sequencing was performed on invasive serogroup Y isolates from 1995 to 2012 in Sweden (n = 18

290 olecule real-time (SMRT) sequencing on eight serogroup Y isolates from different sublineages to unrav

291 se isolates were compared to a collection of serogroup Y isolates from England, Wales, and Northern I

292 Draft genomes of serogroup Y isolates in Sweden revealed that although th

293 cture of these isolates was similar to other serogroup Y isolates internationally, a distinct strain

294 pact of a meningococcal conjugate vaccine on serogroup Y meningococcal carriage and to define the dyn

295 d to reveal additional genes associated with serogroup Y meningococcal disease, and this work would b

296 and this work would benefit from a complete serogroup Y meningococcal reference genome.

297 Invasive meningococcal disease (IMD) due to serogroup Y Neisseria meningitidis emerged in Europe dur

298 obtained in 1999 in the United States, where serogroup Y remains one of the major causes of IMD.

299 There were only 5 observed acquisitions of serogroup Y strains during the study; therefore, the imp

300 cal population structure of Swedish invasive serogroup Y strains to those of other countries with dif

301 Extensive comparisons between the serogroup Y sublineages of all coding sequences, complex